Published on
In a landmark study, an international consortium led by researchers at CHOP published the final results of a key clinical trial of the gene therapy CASGEVY for the treatment of sickle cell disease.
Published on
CHOP has treated its 500th patient with CAR T-cell immunotherapy, a “living drug” that harnesses the power of a patient’s own immune system to fight cancer.
Published on
CHOP will be a provider in Independence Blue Cross’s new Advanced Network for Gene-Based Therapeutics, effective March 1, 2023.
Published on
CHOP researchers have developed a custom-built application to automate determination of engraftment, a key outcome after hematopoietic stem cell transplant.
Published on
Two researchers from Children’s Hospital of Philadelphia (CHOP) were recently selected by the health and science news outlet STAT as 2022 Wunderkinds, an award that celebrates the next generation of scientific superstars who are making significant contributions to biomedical research.
Published on
Researchers from Children’s Hospital of Philadelphia (CHOP) have found that economically disadvantaged children treated with CAR T-cell therapy for relapsed/refractory acute lymphoblastic leukemia (ALL) fair just as well as children from more socioeconomically advantaged backgrounds.
Published on
A leading study site for nearly a decade, CHOP will be part of a network of treatment centers in the country offering the therapy to patients who require regular blood transfusions.
Published on
New data on show CAR T-cell therapy leads to durable remission and long-term survival in children and young adults with relapsed or refractory B-ALL.
Published on
A group of researchers that includes CHOP presented new data on CRISPR-edited gene therapy for blood disorders at an international meeting.
Published on
CHOP researchers have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing.